Document is current
Any future updates will be listed below
-
Authors
Ahn, Jehyun
Yun, Jihwan
Weiner, Michael W.
Shin, Daeun
Kang, Heekyoung
Yim, Sohyun
Kim, Seonghyeon
Park, Heekyoung
Jang, Hyemin
Chun, Min Young
Lee, Eun Hye
Kim, Hee Jin
Na, Duk L.
Kim, Jun Pyo
Seo, Sang Won
,
-
Funding
Funding for this research was provided by:
Korea Dementia Research Center (RS-2020-KH106434)
Korea Health Industry Development Institute (RS-2025-02223212)
National Research Foundation of Korea (RS-2019-NR040057)
Institute of Information & Communications Technology Planning & Evaluation (RS-2021-II212068)
Samsung Medical Center, Sungkyunkwan University (SMX1250081)
Korea National Institute of Health (2024-ER1003-01)
- License Information
-
More Information
Article History
Received: 4 January 2026
Accepted: 8 May 2026
First Online: 21 May 2026
Declarations
Ethics approval and consent to participate: The ADNI study was approved by the institutional review boards of all participating institutions. Written informed consent was obtained from all participants or their authorized representatives in accordance with the Declaration of Helsinki. Further details can be found at .
Consent for publication: Not applicable.
Competing interests: Sang Won Seo has served at scientific advisory boards and/or as a consultant for Quanterix and Eli-Lilly. Sang Won Seo is co-founder of BeauBrain Healthcare Inc.
